Inclusion Criteria:  Histologically confirmed prostate cancer (ICD-O-3 C61) WHO/ECOG performance status 0-1 1-3 skeletal or extra pelvic lymph node metastases detected by PSMA-PET/CT in i. de novo prostate cancer or ii. PSA-relapse after definitive RT or prostatectomy Willing and able to provide informed consent-  Exclusion Criteria:  Castration resistant prostate cancer (progression with castrate levels of testosterone <20ng/dL) Any treatment known to affect PSA (including ADT) for prostate cancer within 6 months (exception: ADT started due to oligometastatic disease within 2 weeks of study entry) Patient eligible for other treatment (e.g., early docetaxel) than standard treatment described in the protocol as judged by treating physician Life expectancy <3 years by any reason, including concomitant or previous malignancies Previous radiotherapy or surgery that may interfere with the planned treatment (including intra-prostatic recurrence if previous RT to the prostate) > 3 PSMA-PET/CT positive target lesions (excluding the prostate in de novo patients or prostate bed post radical prostatectomy) PSMA-PET verified metastases other than skeletal or lymph nodes Metastases in base of scull and/or calotte Any target lesions not treatable with image guided RT (IGRT) due to overlap with previous RT fields or exceeded dose constraint to OAR(s) as specified in study protocol